All In Biotech

Drug Trial Radar · NCT04270669

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

A Nonrandomized, Open-label Study to Evaluate the Safety and Pharmacokinetics of Multiple Administration of RC28-E Injection (a Chimeric Decoy Receptor Trap Fusion Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Wet Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Apr 15, 2020

Primary completion

Oct 29, 2021

Study completion Oct 29, 2021

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple administration.

Conditions

  • Wet Age-Related Macular Degeneration

Interventions

  • intravitreal injection of RC28-E 0.5mgBiological

    The patient received one treatment of RC28-E 0.5mg in the test group

  • intravitreal injection of RC28-E 1.0mgBiological

    The patient received one treatment of RC28-E 1.0mg in the test group

  • intravitreal injection of RC28-E2.0mgBiological

    The patient received one treatment of RC28-E 2.0mg in the test group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change of BCVA from baseline at 12 week;Time frame: Baseline, Week 12
  2. Mean change of BCVA from baseline at 48 week;Time frame: Baseline, Week 48
  3. Incidence and severity of AEsTime frame: Baseline up to Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.